Printer Friendly

INNOVET SUBSIDIARY EARNS SMART AWARD FROM U.K. DEPARTMENT OF TRADE AND INDUSTRY: NEW TECHNOLOGY TO DETECT POTENTIALLY HARMFUL RESIDUES IN MEAT

 WEST PALM BEACH, Fla., Aug. 5 /PRNewswire/ -- InnoVet, Inc. (AMEX: IVT) announced today that its Cambridge Veterinary Sciences (CVS) subsidiary has been awarded the prestigious SMART award (Small Firms Merit Award for Research and Technology) from the U.K. Department of Trade and Industry to assist in developing a new food quality assurance test that detects unsafe levels of drug, pesticide and herbicide residues in meat and milk.
 The technology, based on patented instrumentation developed by Loughborough University of Technology in England and licensed to CVS, is expected to provide a faster, less expensive and more reliable method to measure the "Maximum Residue Limit" (MRL) of residues from veterinary drugs used to treat food-producing animals or from pesticide and herbicide residues acquired by animals through eating contaminated feeds. Antibiotic residues, for example, may cause allergic reactions in some people and may lead to development of antibiotic resistant bacteria in humans.
 The implementation of standardized methodology for residue detection is a high priority of the European Commission. Unlike current methods to measure MRLs, the CVS technology should allow mass sampling and be suitable for routine use in abattoirs and food processing plants.
 The potential U.S. and European Economic Community (EC) markets for food quality assurance tests are estimated to be $100 million annually. They could surpass $200 million by the year 2000. In Europe alone, approximately 132 million cattle and 174 million pigs are slaughtered each year for human consumption and the numbers are much higher in the United States and Far East. In addition, the United States and other areas of the world desiring to import into the EC will have to meet EC standards.
 The CVS technology, which has the potential for full automation, uses specific antibodies, near-infra-red fluorescent labels and a fluorimeter design which should enable food products to be tested on- site, within minutes, by semi-skilled workers at a reasonable cost.
 Some 2,000 to 3,000 companies apply for SMART awards each year, but only 180 were granted. CVS will receive an award of 45,000 pounds sterling (approximately U.S.$67,500). Projects are judged on their quality and uniqueness, the qualifications of the scientists involved and the potential commercial benefit to the United Kingdom, among other criteria.
 Called "ADAM" (Analytical System for the Detection of Antimicrobials in Meat), the technology also has potential for detecting drugs in body fluids, and could therefore be useful in human medicine for therapeutic drug monitoring, blood screening for substance abuse, and toxicology.
 InnoVet, Inc., and its subsidiaries, which have operations in the United States and Europe, is a biotechnology company engaged in research, development and marketing of innovative pharmaceutical, biological, diagnostic and nutritional products. These products and technologies include an immune stimulant, several proprietary drug delivery technologies and a new venture to enter the livestock sex cell separation market. InnoVet's products and technologies are targeted primarily for the animal health care market, but some may also have significant applications in human health and nutrition.
 -0- 8/5/93
 /CONTACT: Dr. Jesse Houdeshell of InnoVet, 407-687-8088, or David Crosson of INFOCUS, 609-683-9055, for InnoVet/
 (IVT)


CO: InnoVet, Inc.; INFOCUS, Inc. ST: New Jersey, Florida IN: ADV SU: PDT

MP-MJ -- PH009 -- 9799 08/05/93 10:40 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 5, 1993
Words:539
Previous Article:NEW VALLEY CORPORATION REPORTS SECOND-QUARTER AND SIX-MONTHS RESULTS
Next Article:RIBI IMMUNOCHEM REPORTS SECOND QUARTER FINANCIAL RESULTS
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters